Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Receivables (2017 - 2026)

Dr Reddys Laboratories has reported Receivables over the past 10 years, most recently at $1.1 billion for Q1 2026.

  • For Q1 2026, Receivables rose 1033.16% year-over-year to $1.1 billion; the TTM value through Mar 2026 reached $1.1 billion, up 1033.16%, while the annual FY2026 figure was $1.1 billion, 4.65% up from the prior year.
  • Receivables for Q1 2026 was $1.1 billion at Dr Reddys Laboratories, up from -$118.7 million in the prior quarter.
  • Over five years, Receivables peaked at $1.1 billion in Q1 2026 and troughed at -$118.7 million in Q1 2025.
  • A 5-year average of $745.4 million and a median of $889.1 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: tumbled 112.26% in 2025 and later surged 1033.16% in 2026.
  • Year by year, Receivables stood at $889.1 million in 2022, then fell by 0.83% to $881.8 million in 2023, then rose by 9.72% to $967.5 million in 2024, then tumbled by 112.26% to -$118.7 million in 2025, then surged by 1033.16% to $1.1 billion in 2026.
  • Business Quant data shows Receivables for RDY at $1.1 billion in Q1 2026, -$118.7 million in Q1 2025, and $967.5 million in Q1 2024.